Table of contents
21 May 2018
Masthead
21 May 2018
Notices
21 May 2018
Hepatology Highlights
Nicholas Russo, Robert S. Brown, Shirley Cohen‐Mekelburg, Robert E. Schwartz, Vikas Gupta, Joseph F. Pisa, Russell Rosenblatt, Aleksey Novikov – 21 May 2018
High Mobility Group Box‐1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice
Xiaodong Ge, Elena Arriazu, Fernando Magdaleno, Daniel J. Antoine, Rouchelle dela Cruz, Neil Theise, Natalia Nieto – 18 May 2018 – High‐mobility group box‐1 (HMGB1) is a damage‐associated molecular pattern (DAMP) increased in response to liver injury. Because HMGB1 is a ligand for the receptor for advanced glycation endproducts (RAGE), we hypothesized that induction of HMGB1 could participate in the pathogenesis of liver fibrosis though RAGE cell‐specific signaling mechanisms.
Reply
Jasmohan S. Bajaj, Tor Savidge, Zain A Kassam, Phillip B. Hylemon, Patrick M. Gillevet – 18 May 2018
Antibiotic‐Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant
Benjamin H. Mullish, Julie A.K. McDonald, Mark R. Thursz, Julian R. Marchesi – 18 May 2018
Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI‐110) in Hepatocellular Carcinoma
Minmin Liu, Lian Zhang, Hongtao Li, Toshinori Hinoue, Wanding Zhou, Hitoshi Ohtani, Anthony El‐Khoueiry, John Daniels, Casey O'Connell, Tanya B. Dorff, Qianjin Lu, Daniel J. Weisenberger, Gangning Liang – 18 May 2018 – There is an urgent need to develop more effective therapies for hepatocellular carcinoma (HCC) because of its aggressiveness. Guadecitabine (SGI‐110) is a second‐generation DNA methyltransferase inhibitor (DNMTi), which is currently in clinical trials for HCC and shows greater stability and performance over first‐generation DNMTis.